Literature DB >> 29435850

Managing Gout in the Patient with Renal Impairment.

Eliseo Pascual1,2, Francisca Sivera3, Mariano Andrés4,5.   

Abstract

Hyperuricaemia is an independent risk factor for renal function decline. Evidence is emerging that urate-lowering therapy might be beneficial in subjects with renal impairment. We  review the association between renal impairment and gout, some of the related pathogenic processes and the possible impact of gout treatment on the progression of renal impairment. Nevertheless, the management of gout is more complex in the presence of chronic kidney disease. The main aim of gout therapy is to fully dissolve the urate crystals, thus curing the disease. Avoidance of attacks-prophylaxis-and their prompt treatment if they occur, along with accurate information to patients, completes the treatment strategy. This article provides a practical guide to managing gout in older patients and in those with renal impairment. We highlight the shortcomings in our current treatment options and strategies.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29435850     DOI: 10.1007/s40266-018-0517-7

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  95 in total

1.  Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol.

Authors:  M K Reinders; E N van Roon; T L Th A Jansen; J Delsing; E N Griep; M Hoekstra; M A F J van de Laar; J R B J Brouwers
Journal:  Ann Rheum Dis       Date:  2008-02-04       Impact factor: 19.103

2.  Mobilization of gouty tophi by protracted use of uricosuric agents.

Authors:  T F YU; A B GUTMAN
Journal:  Am J Med       Date:  1951-12       Impact factor: 4.965

3.  Effectiveness of Anakinra in Acute Gout: A Retrospective Review of Initial and Refractory Therapy.

Authors:  Sarah E Petite
Journal:  Am J Ther       Date:  2017 Sep/Oct       Impact factor: 2.688

4.  2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis.

Authors:  Dinesh Khanna; Puja P Khanna; John D Fitzgerald; Manjit K Singh; Sangmee Bae; Tuhina Neogi; Michael H Pillinger; Joan Merill; Susan Lee; Shraddha Prakash; Marian Kaldas; Maneesh Gogia; Fernando Perez-Ruiz; Will Taylor; Frédéric Lioté; Hyon Choi; Jasvinder A Singh; Nicola Dalbeth; Sanford Kaplan; Vandana Niyyar; Danielle Jones; Steven A Yarows; Blake Roessler; Gail Kerr; Charles King; Gerald Levy; Daniel E Furst; N Lawrence Edwards; Brian Mandell; H Ralph Schumacher; Mark Robbins; Neil Wenger; Robert Terkeltaub
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-10       Impact factor: 4.794

5.  Chronic gouty nephropathy treated by long-term hemodialysis and allopurinol.

Authors:  W J Johnson; J D O'Duffy
Journal:  Mayo Clin Proc       Date:  1979-09       Impact factor: 7.616

6.  Treating hyperuricemia of gout: safety and efficacy of febuxostat and allopurinol in older versus younger subjects.

Authors:  Michael A Becker; Patricia A MacDonald; Barbara Hunt; Lhanoo Gunawardhana
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2011-12       Impact factor: 1.381

7.  Allopurinol in gouty nephropathy and renal dialysis.

Authors:  R W Rundles
Journal:  Ann Rheum Dis       Date:  1966-11       Impact factor: 19.103

8.  Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency.

Authors:  K R Hande; R M Noone; W J Stone
Journal:  Am J Med       Date:  1984-01       Impact factor: 4.965

Review 9.  Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis of observational studies.

Authors:  Matthew J Roughley; John Belcher; Christian D Mallen; Edward Roddy
Journal:  Arthritis Res Ther       Date:  2015-04-01       Impact factor: 5.156

10.  Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney.

Authors:  Jeffrey N Miner; Philip K Tan; David Hyndman; Sha Liu; Cory Iverson; Payal Nanavati; David T Hagerty; Kimberly Manhard; Zancong Shen; Jean-Luc Girardet; Li-Tain Yeh; Robert Terkeltaub; Barry Quart
Journal:  Arthritis Res Ther       Date:  2016-10-03       Impact factor: 5.156

View more
  3 in total

1.  The Occurrence of Nephrolithiasis in Gout Patients: A Longitudinal Follow-Up Study Using a National Health Screening Cohort.

Authors:  So Young Kim; Dae Myoung Yoo; Ji Hee Kim; Mi Jung Kwon; Joo-Hee Kim; Jung Woo Lee; Woo Jin Bang; Hyo Geun Choi
Journal:  Life (Basel)       Date:  2022-04-28

Review 2.  Excess Uric Acid Induces Gouty Nephropathy Through Crystal Formation: A Review of Recent Insights.

Authors:  Yongsheng Mei; Bingzi Dong; Zhuang Geng; Lili Xu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-14       Impact factor: 6.055

3.  Multiple-Purpose Connectivity Map Analysis Reveals the Benefits of Esculetin to Hyperuricemia and Renal Fibrosis.

Authors:  Yiming Wang; Weikaixin Kong; Liang Wang; Tianyu Zhang; Boyue Huang; Jia Meng; Baoxue Yang; Zhengwei Xie; Hong Zhou
Journal:  Int J Mol Sci       Date:  2020-10-18       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.